Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 vs Pemetrexed + Platinum in EGFR-mutated NSCLC after EGFR-TKI failure
NCT05870319Phase 3Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Kelun-Biotech. Primary endpoint: Progression-Free Survival up to 36 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05870319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870319.